Free Trial
NASDAQ:LOGC

LogicBio Therapeutics Q2 2024 Earnings Report

LogicBio Therapeutics EPS Results

Actual EPS
-$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

LogicBio Therapeutics Revenue Results

Actual Revenue
$7.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LogicBio Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
4:00PM ET

LogicBio Therapeutics Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More LogicBio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LogicBio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LogicBio Therapeutics and other key companies, straight to your email.

About LogicBio Therapeutics

LogicBio Therapeutics (NASDAQ:LOGC), a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

View LogicBio Therapeutics Profile

More Earnings Resources from MarketBeat